Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab or benralizumab in severe eosinophilic asthma
2023-510230-84-00Phase 3Completed
- Sponsor
- GSK
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic asthma (EA) comparing Depemokimab arm, Mepolizumab arm and Benralizumab arm (3 arms). Primary endpoint: Annualized rate of clinically significant exacerbations over 52 weeks. Started May 2021; status: completed.
02
Drugs
depemokimabmepolizumabbenralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2023-510230-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510230-84-00.